Development, identification and validation of COVID-19 prognostic and predictive biomarkers tests
A laboratory of an Italian university hospital developed selective chip-panels to detect COVID-19 susceptibility/resistance alleles. Panels are validated in terms of sensitivity, precision and specificity identifying at risk alleles according to clinical phenotypes. Industries or universities are sought for a technical cooperation to extend the product. Pharmaceutical companies or investors are sought for financial or license agreement to further develop the product in diagnostics.